Traduction de «Valvular stenosis » (Anglais → Français) :

valvular stenosis | valve stenosis | heart valve stenosis | cardiac valve stenosis

pulmonary stenosis | PS | pulmonary valve stenosis | pulmonary valvular stenosis | pulmonic stenosis | pulmonic valve stenosis | pulmonic valvular stenosis | PVS

aortic stenosis | AS | aortic valve stenosis | aortic valvular stenosis | AVS

Endocarditis (chronic) NOS Valvular:incompetence | insufficiency | regurgitation | stenosis | Valvulitis (chronic) | of unspecified valve | NOS or of specified cause, except rheumatic or congenital

Congenital valvular pulmonic stenosis

valvular defect | valvular vice

cardiac valvulopathy | valvular disease of the heart | valvular heart disease | valvulopathy

A rare congenital heart malformation with characteristics of tetralogy of Fallot (pulmonary stenosis, overriding aorta, ventricular septal defect and right ventricular hypertrophy), complete absence or rudimentary pulmonary valve that is both stenoti

A rare chromosomal anomaly syndrome with a highly variable phenotype ranging from normal (in the majority of cases) to a mild, subtle phenotype. Principle characteristics are spinal abnormalities (stenosis, vertebral fusion, and kyphosis), hypotonia,

Another very surprising finding, the stenosis of the veins, the usual cardinal criterion for CCSVI, if there is any abnormality at all, from the post-mortem studies that have appeared since or more sophisticated imaging techniques, the real culprit could be perhaps valvular problems in the neck veins and not at all a stenotic problem.

Question No. 53 Ms. Kirsty Duncan: With respect to the chronic cerebrospinal venous insufficiency (CCSVI) clinical trial being undertaken by Dr. Traboulse: (a) what milestones are reportable to the government, (i) on what date(s) is reporting expected to occur, (ii) how will this information be communicated to patients, the medical community, and the general public; (b) on what date did each of the trial sites pass ethical review; (c) on what date did recruitment of patients begin for each of the trial sites; (d) how many patients with multiple sclerosis (MS) are being recruited for each site, and how is consistency in diagnosis and treatment being ensured across sites; (e) who is performing the diagnoses for CCSVI for each site, (i) ho ...[+++]w is the diagnosis being performed, including, but not limited to, ultrasound and venogram, (ii) how many diagnoses has each person undertaking the diagnosis at each site performed prior to the study, and by whom was each person trained; (f) who is performing the procedures for each site, (i) how is the procedure being performed, including, but not limited to, anesthetic, balloon size, (ii) how many procedures has each person undertaking the procedure at each site performed prior to the study, and by whom was each person trained; (g) what are the selection criteria for the trial, including, but not limited to, type of MS, Expanded Disability Status Scale (EDSS) score, venous abnormality/malformed valve/stenosis, mobility, (i) how do these criteria compare with the international literature, (ii) with how many international studies to date will the selection criteria be analytically comparable; (h) if both progressive and relapsing-remitting forms of MS are to be examined in the trial, how will statistical significance be ensured given that 50 of 100 patients will undergo a “sham” procedure, 25 patients will have a progressive form of the disease, and 25 will have a relapsing-remitting form of the disease, and will people with bo ...